ClinicalTrials.gg
CompletedNCT05545111Updated Jul 11, 2025

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia

A Phase 2 interventional study of NBI-1117568 and Placebo in Schizophrenia, sponsored by Neurocrine Biosciences. Completed at 15 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Schizophrenia by Neurocrine Biosciences — 6 open to participants now, 6 under way, 4 of them phase 3. Schizophrenia · Neurocrine Biosciences.

Enrollment
8th of 16
210 · median 165
Started
2022
the only one that year
Phase 2
6 of 16
1 open now
Registered
8th of 16
by date

Among the 16 studies in Schizophrenia by Neurocrine Biosciences, this one is the 8th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 8th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 16 studies in Schizophrenia by Neurocrine Biosciences are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Neurocrine Biosciences, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • schizophrenia
  • NBI-1117568
  • muscarinic
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completed .
  • Subject has a primary diagnosis of schizophrenia.
  • The subject is experiencing an acute exacerbation or relapse of symptoms and currently requires hospitalization.
  • Subjects taking prohibited medications, including antipsychotics, must discontinue before study participation
  • Subject is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements.

Key Exclusion Criteria:

  • An unstable medical condition, chronic disease, or .
  • Considered by the investigator to be at imminent risk of suicide or injury to self or others.
  • Diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening.
  • Positive alcohol test or drug screen for disallowed substances.
  • Have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the subject is not capable of adhering to the protocol requirements.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Dose Level A

    Participant administered Dose Level A (6 weeks)

    Drug: NBI-1117568

  • Experimental
    Dose Level B

    Participant administered Dose Level B (6 weeks)

    Drug: NBI-1117568

  • Experimental
    Dose Level C

    Participant administered Dose Level C (6 weeks)

    Drug: NBI-1117568

  • Experimental
    Dose Level D

    Participant administered Dose Level D (6 weeks)

    Drug: NBI-1117568

  • Placebo comparator
    Placebo Schedule

    Participant administered placebo (6 weeks)

    Drug: Placebo

Interventions

  • Active treatment with orally administered NBI-1117568

  • DrugPlacebo

    Placebo matching NBI-1117568

06

What researchers measure

Primary outcomes

  1. Change from baseline in total Positive and Negative Syndrome Scale (PANSS) score at Week 6

    The PANSS evaluates the severity of various symptoms of schizophrenia, and is commonly used to measure symptom reduction in patients taking antipsychotics. Each item is scored on a 7-point severity scale (1=absent; 2=minimal; 3=mild; 4=moderate; 5=moderate severe; 6=severe; 7=extreme). The PANSS total score is derived from the summation of each item. A higher score indicates greater severity.

    Time frame: Baseline and Week 6

07

Study locations

15 sites
  • Neurocrine Clinical Site
    Little Rock, Arkansas 72211, United States
  • Neurocrine Clinical Site
    Rogers, Arkansas 72758, United States
  • Neurocrine Clinical Site
    Lemon Grove, California 91945, United States
  • Neurocrine Clinical Site
    Pico Rivera, California 90660, United States
  • Neurocrine Clinical Site
    San Diego, California 92123, United States
  • Neurocrine Clinical Site
    Torrance, California 90502, United States
  • Neurocrine Clinical Site
    Miami Lakes, Florida 33016, United States
  • Neurocrine Clinical Site
    Oakland Park, Florida 33334, United States
  • Neurocrine Clinical Site
    Gaithersburg, Maryland 20877, United States
  • Neurocrine Clinical site
    St Louis, Missouri 63141, United States
  • Neurocrine Clinical Site
    Berlin, New Jersey 08053, United States
  • Neurocrine Clinical Site
    North Canton, Ohio 44720, United States
  • Neurocrine Clinical Site
    Austin, Texas 78754, United States
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
  • Neurocrine Clinical Site
    Richardson, Texas 75080, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jul 2024, 21 months.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 21 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 19, 2022
StartActual
Oct 4, 2022
Primary completionActual
Jul 10, 2024
CompletionActual
Jul 10, 2024
Results delay requested
Jul 9, 2025
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05545111
Responsible party
Sponsor
First posted
Sep 19, 2022
Start date
Oct 4, 2022
Primary completion
Jul 10, 2024
Completion
Jul 10, 2024
Last update
Jul 11, 2025

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Direclidine

Start the discussion